• 81
  • 14
  • Favorite

WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool

Reuters2022-01-14

A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.

WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.

The panel on Thursday strongly recommended Lilly's baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir's antibody therapy for non-severe patients at the highest risk of hospitalization.

So far, GSK-Vir's monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and Regeneron Pharmaceuticals offered lower protection in such tests.

The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body's natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.

The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.

French medical charity Medecins Sans Frontieres $(MSF)$ welcomed the United Nations agency's guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.

MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment14

  • fariqsaid
    ·2022-01-14
    Nice
    Reply
    Report
  • Tiramisu2020
    ·2022-01-14
    Cool
    Reply
    Report
  • Pandachubby
    ·2022-01-14
    Ok
    Reply
    Report
  • girritant
    ·2022-01-14
    Great news!
    Reply
    Report
  • Sethiroth
    ·2022-01-14
    Like
    Reply
    Report
  • ivy888
    ·2022-01-14
    Like 
    Reply
    Report
  • OddEyeCircle
    ·2022-01-14
    Perfect 🥰🥰🥰🥰
    Reply
    Report
  • wincephine
    ·2022-01-14
    Yes
    Reply
    Report
  • kcwang4982
    ·2022-01-14
    Like
    Reply
    Report
  • Yee ying
    ·2022-01-14
    like
    Reply
    Report
  • Milkgonebad
    ·2022-01-14
    Nice
    Reply
    Report
  • VLBL
    ·2022-01-14
    Like
    Reply
    Report
  • WeiChongkan
    ·2022-01-14
    liked
    Reply
    Report
  • rocketship
    ·2022-01-14
    Like
    Reply
    Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial